Multicentric Castleman’s disease in HIV patients: a single-center cohort diagnosed from 2008 to 2018

Gliga, Smaranda; Orth, Hans Martin; Lübke, Nadine; Timm, Jörg; Luedde, Tom; Jensen, Björn‐Erik Ole

doi:10.1007/s15010-021-01618-5

Cited by 3 publications

(3 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[7][8][9][10][11][12] Another eight studies did not provide information on our de ned primary endpoint. [13][14][15][16][17][18][19][20] 43 studies investigated the effect of CytoSorb® in children. One study was excluded because the group size was too small (n = 2) and another study was excluded due to the lack of standard therapy in the control group.…”

Section: Resultsmentioning

confidence: 99%

Efficacy of CytoSorb® - A Metaanalysis

Becker

Lang

Barbosa

et al. 2022

Preprint

View full text Add to dashboard Cite

Cytokine adsorption using the CytoSorb® device has been proposed in various clinical settings including sepsis, ARDS, hyperinflammatory syndromes, cardiac surgery or recovery after cardiac arrest. The aim of this analysis is to provide evidence for the efficacy of the CytoSorb® device with regard to mortality in various settings. Methods: We searched PubMed, Cochrane Library database and the database provided by Cytosorbents™ (01.1.2010–29.5.2022). We considered randomized controlled trials and intervention studies with control groups. The longest reported mortality was defined as primary endpoint. For analyzing the data, we computed risk ratios and 95%-confidence intervals and used DerSimonian and Lairds random effects model. We analyzed all studies combined and divided into the subgroups sepsis, cardiac surgery, other severe illness, SARS-CoV-2 infection and recovery from cardiac arrest. The meta-analysis was registered in advance (PROSPERO: CRD42022290334). Results: Of an initial 1295 publications, 34 studies were found eligible, including 1297 patients treated with CytoSorb® and 1314 controls. Cytosorb® did not lower mortality in all studies together (1.07 [0.88; 1.31] RR [95%-CI]), in sepsis (0.98 [0.74; 1.31]), CPB surgery (0.91 [0.64; 1.29]), severe illness (0.95 [0.59; 1.55]) or SARS-CoV-2 (1.58 [0.50; 4.94]). In patients with cardiac arrest, we found a significant survival advantage of the untreated controls (RR 1.22 [1.02; 1.46]). We did not find significant differences in ICU length of stay, lactate levels, or IL-6 levels after treatment. Interpretation: To date there is no evidence for a positive effect of the CytoSorb® adsorber on mortality across a variety of indications that justifies its widespread use in intensive care medicine.

show abstract

Section: Resultsmentioning

confidence: 99%

Efficacy of CytoSorb® - A Metaanalysis

Becker

Lang

Barbosa

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…We noted improved outcomes in our patients with MCD compared to historical data. Prior studies have reported a median survival of 2 years if MCD is left untreated, 19 and a 1‐year survival estimated at 54%–87.5% 19,29 . In this study, we have at least 1‐year of follow‐up data for 9 of our 10 patients.…”

Section: Discussionmentioning

confidence: 95%

“…Prior studies have reported a median survival of 2 years if MCD is left untreated, 19 and a 1-year survival estimated at 54%-87.5%. 19,29 In this study, we have at least 1-year of follow-up data for 9 of our 10 patients. Of these nine patients, seven (78%)…”

Section: Discussionmentioning

confidence: 99%

Outcomes in Kaposi's sarcoma‐associated herpesvirus ‐associated primary effusion lymphoma and multicentric Castleman's disease in patients with human immunodeficiency virus (HIV) in a safety‐net hospital system

Lopez,

Kainthla,

Lazarte

et al. 2023

European J of Haematology

View full text Add to dashboard Cite

ObjectiveTo describe cases of Kaposi's sarcoma‐associated herpesvirus (KSHV)‐associated multicentric Castleman's disease (MCD) and primary effusion lymphoma (PEL) in patients with HIV from a large, safety‐net hospital system in Dallas, Texas, USA.MethodsWe conducted a retrospective review of patients with HIV‐associated PEL and/or MCD.ResultsTwelve patients with PEL and 10 patients with MCD were identified. All patients were male and 17 of 20 were men who have sex with men; 66.7% of PEL patients and 50% of MCD patients had concurrent KS at the time of diagnosis; 42% of patients with PEL and 20% of patients with MCD died during the follow‐up period. We noted improved survival in our cohort compared to previous studies, particularly in our PEL patients with a median survival of 11.4 months compared to 3–6‐month median survival historically. Median follow‐up time for MCD patients was 17.5 months. This improved survival is despite suboptimal antiretroviral therapy (ART) adherence at diagnosis, with only 50% of patients on ART at the time of MCD/PEL diagnosis.ConclusionThese data highlight the importance of early recognition of PEL and MCD, and the larger‐scale efforts needed to better understand the pathogenetic drivers of clinical outcomes in patients affected by KSHV‐related diseases.

show abstract

Efficacy of CytoSorb®: a systematic review and meta-analysis

et al. 2023

View full text Add to dashboard Cite

Introduction Cytokine adsorption using the CytoSorb® adsorber has been proposed in various clinical settings including sepsis, ARDS, hyperinflammatory syndromes, cardiac surgery or recovery after cardiac arrest. The aim of this analysis is to provide evidence for the efficacy of the CytoSorb® adsorber with regard to mortality in various settings. Methods We searched PubMed, Cochrane Library database and the database provided by Cytosorbents™ (01.1.2010–29.5.2022). We considered randomized controlled trials and observational studies with control groups. The longest reported mortality was defined as the primary endpoint. We computed risk ratios and 95%-confidence intervals and used DerSimonian and Lairds random effects model. We analysed all studies combined and divided them into the subgroups: sepsis, cardiopulmonary bypass surgery (CPB), other severe illness, SARS-CoV-2 infection and recovery from cardiac arrest. The meta-analysis was registered in advance (PROSPERO: CRD42022290334). Results Of an initial 1295 publications, 34 studies were found eligible, including 1297 patients treated with CytoSorb® and 1314 controls. Cytosorb® intervention did not lower mortality (RR [95%-CI]: all studies 1.07 [0.88; 1.31], sepsis 0.98 [0.74; 1.31], CPB surgery 0.91 [0.64; 1.29], severe illness 0.95 [0.59; 1.55], SARS-CoV-2 1.58 [0.50; 4.94]). In patients with cardiac arrest, we found a significant survival advantage of the untreated controls (1.22 [1.02; 1.46]). We did not find significant differences in ICU length of stay, lactate levels, or IL-6 levels after treatment. Of the eligible 34 studies only 12 were randomized controlled trials. All observational studies showed moderate to serious risk of bias. Interpretation To date, there is no evidence for a positive effect of the CytoSorb® adsorber on mortality across a variety of diagnoses that justifies its widespread use in intensive care medicine.

show abstract

Multicentric Castleman’s disease in HIV patients: a single-center cohort diagnosed from 2008 to 2018

Cited by 3 publications

References 34 publications

Efficacy of CytoSorb® - A Metaanalysis

Efficacy of CytoSorb® - A Metaanalysis

Outcomes in Kaposi's sarcoma‐associated herpesvirus ‐associated primary effusion lymphoma and multicentric Castleman's disease in patients with human immunodeficiency virus (HIV) in a safety‐net hospital system

Efficacy of CytoSorb®: a systematic review and meta-analysis

Contact Info

Product

Resources

About